What is ‘judicious use of antibiotics’ and is it achievable in children? Academic Article uri icon


  • Best practice strategies regarding primary antifungal prophylaxis in leukemia patients and in hematopoietic stem cell transplant recipients continue to evolve. For this prophylaxis to be beneficial and cost-effective, the risk of a life-threatening invasive fungal infection (IFI) should outweigh the risks of toxic effects and drug interactions introduced by the antifungal agent used. Furthermore, the improved survival of such patients with IFIs creates pressing issues regarding optimization of secondary antifungal prophylaxis. Not all patients with hematologic cancer recipients have the same risk of IFIs. Well tolerated and pharmacokinetically reliable, broad-spectrum antifungals, especially azoles, have the potential for reducing IFI-associated mortality in these patients. Further refinement of risk stratification and risk/benefit analysis (including pharmacoeconomic analysis) is needed …

publication date

  • April 1, 2014